PIK3CA and melanoma: While prior studies of MEK inhibition in CRC and melanoma have indicated resistance through PI3K pathway activation, our results were not consistent across multiple models, and may in fact, reflect the fact that at least in the case of CRC, combinations of PI3K and MEK inhibitors have not been particularly active in the clinic [29, 30].